Genetic Hardwiring Blamed for Most High Cholesterol as Germany Faces €50.6 Billion Heart-Disease Tab
12.06.2026 - 11:03:28 | boerse-global.de
Seventy to 80 percent of an individual's LDL cholesterol level is determined by genetics, leaving diet and exercise to influence only 20 to 30 percent. That sobering assessment, released by the German Heart Foundation ahead of Cholesterol Day on 12 June 2026, challenges the common assumption that lifestyle changes alone can fix dangerous lipid profiles.
Even an optimal regimen of healthy eating and physical activity can lower LDL by no more than 10 to 20 percent, the foundation noted. For patients already at high cardiovascular risk, that range is rarely enough. The European Society of Cardiology's 2025 guidelines set aggressive treatment targets: below 55 mg/dL for very high risk and below 70 mg/dL for high risk. Experts from the German Society for Lipidology stress that measuring not just LDL but also triglycerides and lipoprotein(a) is essential for early detection of atherosclerosis, heart attacks and strokes. According to the Heart Foundation, a low LDL reading is hardly ever a concern.
A €50.6 Billion Burden
The genetic dimension emerges as a new report quantifies the economic toll of elevated cholesterol and its downstream effects. Commissioned by MSD and produced by OHE London, the 2024 analysis puts direct and indirect costs of atherosclerotic cardiovascular disease at 17.3 billion euros annually. That figure sits inside a much larger bill: all cardiovascular diseases together cost Germany 50.6 billion euros per year.
Of that total, 22 billion euros goes to medical services. The remaining 28.7 billion euros stems from lost productivity — sick leave and premature exits from the workforce. Per patient, the yearly economic load clocks in at roughly 2,200 euros. Heart disease remains Germany's leading cause of death, with more than 185,000 people hospitalised for heart attacks each year. The Rhön-Klinikum AG warns that over 80 percent of cardiovascular risk patients are not therapeutically optimised.
Industry Fears Over GKV Austerity
A parallel dispute over healthcare financing threatens to compound the medical challenge. The pharmaceutical industry, represented by the Federal Association of the Pharmaceutical Industry (BPI), points out that the health sector anchors roughly 8 million jobs and contributes 12.5 percent of Germany's gross value added.
BPI chairman Oliver Kirst warns that every euro of mandatory rebate imposed on drugmakers by statutory health insurers (GKV) triggers a value-added loss of 3.80 euros. Cumulatively, he argues, the cuts could erode up to 48 billion euros in economic output by 2030. GKV spending on medications has already surged from 27 billion euros in 2012 to a projected 59 billion euros in 2025. A Prognos study commissioned by the INSM puts total GKV expenditure for 2025 at 352 billion euros.
The consequences are tangible. Pfizer chief Albert Bourla has said planned investments in Germany are under review because of the GKV savings law. Eli Lilly and Boehringer Ingelheim have already indicated they are scaling back or scrapping investment projects worth hundreds of millions to billions of euros. The conflict puts at risk a sector that, even without the additional genetic burden of cholesterol, is already absorbing an ever-larger share of national resources.
